A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

NCT00306267 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
61
Enrollment
INDUSTRY
Sponsor class

Stopped Study stopped as it would not address important survival concerns raised in other recently conducted clinical studies.

Conditions

Interventions

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators